Novabiotics, Taro Ink Alliance For Phase IIb-Ready Antifungal
By Nuala Moran
Tuesday, September 3, 2013
LONDON – Novabiotics Ltd. rejected a new round of private funding in favor of an exclusive licensing deal with Taro Pharmaceuticals North America Inc., for the co-development of its first-in-class antifungal peptide Novexatin, which is about to enter Phase IIb development in the treatment of nail infection onychomycosis.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.